塞来昔布
生物利用度
药代动力学
药理学
吸收(声学)
胶囊
十二指肠
口服
医学
胃肠道
空肠
化学
内科学
生物
声学
物理
植物
作者
Susan K. Paulson,Margaret B. Vaughn,Susan M. Jessen,Yvette M. Lawal,Christopher J. Gresk,Bo Yan,Timothy J. Maziasz,Chyung S. Cook,Aziz Karim
标识
DOI:10.1016/s0022-3565(24)29580-x
摘要
Celecoxib pharmacokinetics was evaluated after single and multiple oral dosing; after dosing in a solution and as a solid; with and without food; and after administration into different sites of the GI tract using dog. After oral dosing in a solution, celecoxib was rapidly absorbed and reached maximum concentrations by 1 h; absorption was delayed another 1 to 2 h when administered as a solid. The absolute bioavailability of celecoxib was higher when given as a solution (64--88%) compared with capsule (22--40%). The absorption of celecoxib given in a capsule was delayed by food, although systemic exposure increased by 3- to 5-fold. The systemic availability of celecoxib given intragastrically in solution was similar to that obtained following direct instillation into the duodenum, jejunum, or colon through a chronic intestinal access port. Collectively, these data suggest that celecoxib is a highly permeable drug that can be absorbed throughout the GI tract and that dissolution may be a rate-limiting factor for absorption from solid dosage forms. Unlike dogs, celecoxib given to humans with a high fat meal exhibits only a slight increase in AUC(0--infinity) (11%) that is not clinically significant with regard to safety or efficacy. In humans, a lower dose and a longer GI residence time may promote the opportunity for absorption of a poorly soluble drug such as celecoxib that can be absorbed throughout the GI tract. This would minimize the effect of food on absorption; as such, patients with arthritis can be given celecoxib with or without food.
科研通智能强力驱动
Strongly Powered by AbleSci AI